Boehringer Ingelheim Group

About Boehringer Ingelheim Group

Boehringer Ingelheim Group is a global leader in the pharmaceutical industry, dedicated to researching, developing, manufacturing, and marketing innovative healthcare solutions. Founded in 1885, the company has a rich history of commitment to improving the health and quality of life for humans and animals alike.

With a strong focus on innovation, Boehringer Ingelheim invests heavily in research and development, striving to bring new therapies to market that address unmet medical needs. The company operates in several therapeutic areas, including respiratory diseases, cardiovascular health, oncology, and immunology.

In addition to its human pharmaceuticals division, Boehringer Ingelheim is also a prominent player in the animal health sector, providing vaccines and treatments that enhance the well-being of livestock and pets.

The company’s vision is to create value through innovation, ensuring that their products not only meet the highest standards of quality but also contribute positively to society. Boehringer Ingelheim is committed to sustainability and ethical practices, aiming to reduce its environmental footprint while enhancing access to healthcare globally.

With a workforce of over 50,000 employees worldwide, Boehringer Ingelheim fosters a culture of collaboration and respect, encouraging its team members to contribute to the company’s mission of advancing health and well-being.

Headquartered in Ingelheim am Rhein, Germany, the company has a significant presence in the UK, where it continues to expand its operations and partnerships with local healthcare providers and research institutions.

Through its dedication to scientific excellence and patient-centric approaches, Boehringer Ingelheim Group remains at the forefront of the pharmaceutical industry, making a lasting impact on global health.